Literature DB >> 26629233

Pulmonary arterial hypertension associated with rare cause of ANCA-associated vasculitis misdiagnosed as idiopathic one.

Yi Li1, Qun Yi2.   

Abstract

Pulmonary arterial hypertension (PAH) and ANCA-associated vasculitis (AAV) are both rare and complex diseases with poor prognosis especially when misdiagnosis. We report a rare case of a young woman presented with idiopathic pulmonary arterial hypertension (IPAH), but who was later found to have PAH associated with AAV. This case reminds us the very importance of differential diagnosis to PAH patients and the identification of rare cause likes ANCA-associated vasculitis. To our knowledge, this patient represents the first published case of misdiagnosis of PAH secondary to ANCA-associated vasculitis.

Entities:  

Keywords:  ANCA-associated vasculitis; Pulmonary arterial hypertension

Year:  2015        PMID: 26629233      PMCID: PMC4659121     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  10 in total

Review 1.  Imaging in vasculitis.

Authors:  Wolfgang A Schmidt
Journal:  Best Pract Res Clin Rheumatol       Date:  2013-02       Impact factor: 4.098

Review 2.  Diagnostic and pathogenetic role of antineutrophil cytoplasmic autoantibodies.

Authors:  Jirina Bartůnková; Vladimír Tesar; Anna Sedivá
Journal:  Clin Immunol       Date:  2003-02       Impact factor: 3.969

Review 3.  ANCA glomerulonephritis and vasculitis: a Chapel Hill perspective.

Authors:  R J Falk; P H Nachman; S L Hogan; J C Jennette
Journal:  Semin Nephrol       Date:  2000-05       Impact factor: 5.299

4.  Diagnostic performance of antineutrophil cytoplasmic antibody tests for idiopathic vasculitides: metaanalysis with a focus on antimyeloperoxidase antibodies.

Authors:  H K Choi; S Liu; P A Merkel; G A Colditz; J L Niles
Journal:  J Rheumatol       Date:  2001-07       Impact factor: 4.666

5.  Long-term follow-up study of periarteritis nodosa.

Authors:  P P Frohnert; S G Sheps
Journal:  Am J Med       Date:  1967-07       Impact factor: 4.965

6.  Prognostic impact of pulmonary arterial hypertension: a population-based analysis.

Authors:  Melinda Carrington; Niamh F Murphy; Geoff Strange; Andrew Peacock; John J V McMurray; Simon Stewart
Journal:  Int J Cardiol       Date:  2007-04-11       Impact factor: 4.164

7.  ANCA and predicting relapse in systemic vasculitis.

Authors:  D R Jayne; G Gaskin; C D Pusey; C M Lockwood
Journal:  QJM       Date:  1995-02

8.  Improved outcome in Wegener's granulomatosis and microscopic polyangiitis? A retrospective analysis of 95 cases in two cohorts.

Authors:  P Eriksson; L Jacobsson; A Lindell; J-A Nilsson; T Skogh
Journal:  J Intern Med       Date:  2008-12-23       Impact factor: 8.989

Review 9.  Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force.

Authors:  C Mukhtyar; O Flossmann; B Hellmich; P Bacon; M Cid; J W Cohen-Tervaert; W L Gross; L Guillevin; D Jayne; A Mahr; P A Merkel; H Raspe; D Scott; J Witter; H Yazici; R A Luqmani
Journal:  Ann Rheum Dis       Date:  2007-10-02       Impact factor: 19.103

10.  Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

Authors:  G E D'Alonzo; R J Barst; S M Ayres; E H Bergofsky; B H Brundage; K M Detre; A P Fishman; R M Goldring; B M Groves; J T Kernis
Journal:  Ann Intern Med       Date:  1991-09-01       Impact factor: 25.391

  10 in total
  2 in total

1.  Echocardiographic features in patients with ANCA-associated vasculitis within 3 months before and after diagnosis.

Authors:  Sung Soo Ahn; Eun Seong Park; Seung Min Jung; Jason Jungsik Song; Yong-Beom Park; Sang-Won Lee
Journal:  Clin Rheumatol       Date:  2017-10-08       Impact factor: 2.980

Review 2.  Novel insights on the pulmonary vascular consequences of COVID-19.

Authors:  François Potus; Vicky Mai; Marius Lebret; Simon Malenfant; Emilie Breton-Gagnon; Annie C Lajoie; Olivier Boucherat; Sébastien Bonnet; Steeve Provencher
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-06-17       Impact factor: 5.464

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.